BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37634597)

  • 1. Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.
    Budagaga Y; Sabet Z; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
    Biochem Pharmacol; 2023 Oct; 216():115769. PubMed ID: 37634597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study.
    Sabet Z; Vagiannis D; Budagaga Y; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.
    Vagiannis D; Zhang Y; Budagaga Y; Novotna E; Skarka A; Kammerer S; Küpper JH; Hofman J
    Toxicol Appl Pharmacol; 2022 Jan; 434():115823. PubMed ID: 34896433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
    Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
    Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
    Hofman J; Sorf A; Vagiannis D; Sucha S; Kammerer S; Küpper JH; Chen S; Guo L; Ceckova M; Staud F
    Mol Pharm; 2019 Nov; 16(11):4436-4450. PubMed ID: 31633365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme.
    Vagiannis D; Novotna E; Skarka A; Kammerer S; Küpper JH; Chen S; Guo L; Staud F; Hofman J
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo.
    Zhang Y; Vagiannis D; Budagaga Y; Sabet Z; Hanke I; Rozkoš T; Hofman J
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
    Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
    Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo.
    Vagiannis D; Budagaga Y; Morell A; Zhang Y; Novotná E; Skarka A; Kammerer S; Küpper JH; Hanke I; Rozkoš T; Hofman J
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
    Cihalova D; Staud F; Ceckova M
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo.
    Zhang Y; Vagiannis D; Budagaga Y; Sabet Z; Hanke I; Rozkoš T; Hofman J
    Biochem Pharmacol; 2022 May; 199():115009. PubMed ID: 35314165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy
    Wu X; Yin C; Ma J; Chai S; Zhang C; Yao S; Kadioglu O; Efferth T; Ye Y; To KK; Lin G
    Acta Pharm Sin B; 2021 Jul; 11(7):1885-1902. PubMed ID: 34386326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Teng QX; Chen ZS; Kong D; Yang DH
    Front Pharmacol; 2018; 9():1236. PubMed ID: 30425643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Zhang W; Fan YF; Cai CY; Wang JQ; Teng QX; Lei ZN; Zeng L; Gupta P; Chen ZS
    Front Pharmacol; 2018; 9():1097. PubMed ID: 30356705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.